REGENXBIO INC (RGNX)

US75901B1070 - Common Stock

7.69  +0.07 (+0.92%)

Fundamental Rating

3

RGNX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While RGNX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, RGNX is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RGNX has reported negative net income.
In the past year RGNX has reported a negative cash flow from operations.
In the past 5 years RGNX reported 4 times negative net income.
RGNX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

RGNX has a Return On Assets of -46.00%. This is comparable to the rest of the industry: RGNX outperforms 50.18% of its industry peers.
Looking at the Return On Equity, with a value of -79.23%, RGNX is in line with its industry, outperforming 52.31% of the companies in the same industry.
Industry RankSector Rank
ROA -46%
ROE -79.23%
ROIC N/A
ROA(3y)-22.69%
ROA(5y)-20.56%
ROE(3y)-40.7%
ROE(5y)-34.52%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 54.36%, RGNX is in the better half of the industry, outperforming 77.94% of the companies in the same industry.
In the last couple of years the Gross Margin of RGNX has declined.
The Profit Margin and Operating Margin are not available for RGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.58%
GM growth 5Y-9.28%

More info and screens

6

2. Health

2.1 Basic Checks

RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RGNX has been increased compared to 1 year ago.
The number of shares outstanding for RGNX has been increased compared to 5 years ago.
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

RGNX has an Altman-Z score of -2.24. This is a bad value and indicates that RGNX is not financially healthy and even has some risk of bankruptcy.
RGNX's Altman-Z score of -2.24 is in line compared to the rest of the industry. RGNX outperforms 51.96% of its industry peers.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.24
ROIC/WACCN/A
WACC10.91%

2.3 Liquidity

RGNX has a Current Ratio of 3.05. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
RGNX's Current ratio of 3.05 is on the low side compared to the rest of the industry. RGNX is outperformed by 63.88% of its industry peers.
A Quick Ratio of 3.05 indicates that RGNX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.05, RGNX is not doing good in the industry: 61.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.05
Quick Ratio 3.05

More info and screens

4

3. Growth

3.1 Past

RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.72%, which is quite good.
RGNX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.08%.
Measured over the past years, RGNX shows a very negative growth in Revenue. The Revenue has been decreasing by -16.21% on average per year.
EPS 1Y (TTM)16.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.02%
Revenue 1Y (TTM)-15.08%
Revenue growth 3Y-16.43%
Revenue growth 5Y-16.21%
Sales Q2Q%-16.31%

3.2 Future

Based on estimates for the next years, RGNX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.83% on average per year.
The Revenue is expected to grow by 39.88% on average over the next years. This is a very strong growth
EPS Next Y18.91%
EPS Next 2Y36.15%
EPS Next 3Y11.46%
EPS Next 5Y15.83%
Revenue Next Year-11.44%
Revenue Next 2Y74.46%
Revenue Next 3Y22.81%
Revenue Next 5Y39.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RGNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.15%
EPS Next 3Y11.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RGNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGENXBIO INC

NASDAQ:RGNX (12/23/2024, 9:56:38 AM)

7.69

+0.07 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners92.41%
Inst Owner Change-0.48%
Ins Owners7.15%
Ins Owner Change20.55%
Market Cap381.04M
Analysts84.21
Price Target36.72 (377.5%)
Short Float %11.52%
Short Ratio5.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.03%
Min EPS beat(2)-2.21%
Max EPS beat(2)20.28%
EPS beat(4)1
Avg EPS beat(4)1.04%
Min EPS beat(4)-10.34%
Max EPS beat(4)20.28%
EPS beat(8)3
Avg EPS beat(8)-1.46%
EPS beat(12)4
Avg EPS beat(12)-2.09%
EPS beat(16)5
Avg EPS beat(16)-15.05%
Revenue beat(2)1
Avg Revenue beat(2)-2.14%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)0.57%
Revenue beat(4)1
Avg Revenue beat(4)-18.78%
Min Revenue beat(4)-35.95%
Max Revenue beat(4)0.57%
Revenue beat(8)2
Avg Revenue beat(8)-20.84%
Revenue beat(12)4
Avg Revenue beat(12)-12.06%
Revenue beat(16)4
Avg Revenue beat(16)-17.73%
PT rev (1m)-5.47%
PT rev (3m)-5.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.45%
EPS NY rev (1m)-1.54%
EPS NY rev (3m)-3.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.01%
Revenue NY rev (1m)-5.16%
Revenue NY rev (3m)-6.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.52
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-4.98
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.68
OCFYN/A
SpS1.7
BVpS6.08
TBVpS6.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46%
ROE -79.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.36%
FCFM N/A
ROA(3y)-22.69%
ROA(5y)-20.56%
ROE(3y)-40.7%
ROE(5y)-34.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.58%
GM growth 5Y-9.28%
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.24%
Cap/Sales 2.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.05
Quick Ratio 3.05
Altman-Z -2.24
F-Score4
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)390.86%
Cap/Depr(5y)331.06%
Cap/Sales(3y)18.73%
Cap/Sales(5y)21.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.02%
EPS Next Y18.91%
EPS Next 2Y36.15%
EPS Next 3Y11.46%
EPS Next 5Y15.83%
Revenue 1Y (TTM)-15.08%
Revenue growth 3Y-16.43%
Revenue growth 5Y-16.21%
Sales Q2Q%-16.31%
Revenue Next Year-11.44%
Revenue Next 2Y74.46%
Revenue Next 3Y22.81%
Revenue Next 5Y39.88%
EBIT growth 1Y6.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.52%
EBIT Next 3Y17.06%
EBIT Next 5Y15.81%
FCF growth 1Y-238.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-205.14%
OCF growth 3YN/A
OCF growth 5YN/A